As a statistician and math enthusiast, it was torture reviewing released Northwest Bio’s (OTCQB:NWBO) blinded data, and updated statistics showcasing the blinded results of the DCVax-L Phase III trial from back in June 2018. Reading the positive outlook of the trial through the eyes of the company, and then reading comment upon comment negating results, poking holes in the data, or minimizing the results sparked (or even inflamed) a curiosity in me to dig deep into these freshly provided nuggets of data. Having analyzed the Phase I/II data numerous years in the past,